Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Brazil replaces injured goalkeeper Ederson in Copa America squad
Vogue Williams debuts her new cropped hairdo
Judge hits the tiebreaking single in 9th as Yankees rally to avoid sweep with 6
Jill Biden says an agreement to let federal employee military spouses work from overseas is overdue
Grant Shapps vows he WILL find more planes for mass parachute drop to mark 80th anniversary of D
Influencer, 22, left with second
Judge hits the tiebreaking single in 9th as Yankees rally to avoid sweep with 6
Sydney boy accused of stabbing 2 clerics showed no signs of radicalization, Muslim leader says
Hollywood star Shia LaBeouf is spotted on the streets of Gavin and Stacey's hometown Barry
Kim Kardashian credits North West, 10, for taking her sultry vacation pictures in Turks and Caicos
'Real life' Martha from Baby Reindeer's million
Jury selection in Trump hush money trial faces pivotal stretch as former president returns to court